Oriahnn (Copackaged) is owned by Abbvie Inc.
Oriahnn (Copackaged) contains Elagolix Sodium,Estradiol,Norethindrone Acetate; Elagolix Sodium.
Oriahnn (Copackaged) has a total of 5 drug patents out of which 0 drug patents have expired.
Oriahnn (Copackaged) was authorised for market use on 29 May, 2020.
Oriahnn (Copackaged) is available in capsule;oral dosage forms.
Oriahnn (Copackaged) can be used as management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids).
Drug patent challenges can be filed against Oriahnn (Copackaged) from July, 2022.
The generics of Oriahnn (Copackaged) are possible to be released after 14 March, 2034.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7419983||ABBVIE INC||Gonadotropin-releasing hormone receptor antagonists and methods related thereto|| |
(1 year, 4 months from now)
|US7056927||ABBVIE INC||Gonadotropin-releasing hormone receptor antagonists and methods relating thereto|| |
(1 year, 7 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11459305||ABBVIE INC||Processes for the preparation of uracil derivatives|| |
(5 years from now)
|US10881659||ABBVIE INC||Methods of treating heavy menstrual bleeding|| |
(11 years from now)
|US11045470||ABBVIE INC||Methods of treating heavy menstrual bleeding|| |
(11 years from now)
|New Chemical Entity Exclusivity (NCE)||Jul 23, 2023|
|New Product (NP)||May 29, 2023|
NCE-1 date: July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic